B-Type Natriuretic Peptides (BNP) and Tissue Doppler E/e´ Before and After 4 Weeks Standard Treatment of African Heart Failure Subjects: The ABU-BNP Longitudinal Survey

References

• Weber M, Hamm C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart. 2006;92(6):843–849. doi:10.1136/hrt.2005.07123316698841
   PubMed Web of Science ®Google Scholar
• Palazzuoli A, Beltrami M, Ruocco G, Pellegrini M, Nuti R. The role of natriuretic peptides for the diagnosis of left ventricular dysfunction. Sci World J. 2013;784670–784680. doi:10.1155/2013/784670.10
   Google Scholar
• Dokainish H, Zoghbi WA, Lakkis NM, et al. Incremental predictive power of B-type natriuretic peptide and tissue doppler echocardiography in the prognosis of patients with congestive heart failure. J Am Coll Cardiol. 2005;45(8):1223–1226. doi:10.1016/j.jacc.2005.01.02515837253
   PubMed Web of Science ®Google Scholar
• Ito K, Kawai M, Nakane T, et al. Serial measurements associated with an amelioration of acute heart failure: analysis of repeated quantification of plasma brain natriuretic peptide levels. Eur Heart J. 2012;1(3):240–247.
   Google Scholar
• Al Bannay R, Husain AA. Role of tissue Doppler imaging in assessing left ventricular diastolic dysfunction severity. Does it hold the same ability? Said Med J. 2012;33(1):34–38.
   PubMed Web of Science ®Google Scholar
• Doust J, Lehman R, Glasziou P. The role of B-type natriuretic peptide testing in heart failure. Am Fam Phys. 2006;74(11):1893–1900.
   PubMed Web of Science ®Google Scholar
• Silver W, Maisel A, Yancy CW, et al. Brain natriuretic peptide consensus panel 2004; a clinical approach for the diagnostic, prognostic, screening, treatment, monitoring and therapeutic roles of natriuretic peptides in cardiovascular disease. Cong Heart Fail. 2004;5(3):1–30.
   Google Scholar
• Desai SA. Are serial BNP measurements useful in heart failure management: the art of medicine remains long. Circulation. 2013;127(4):509–516. doi:10.1161/CIRCULATIONAHA.112.12049323357663
   PubMed Web of Science ®Google Scholar
• Troughton RW, Frampton CM, Yandle TG, Espine EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma amino terminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000;355(9210):1126–1130. doi:10.1016/S0140-6736(00)02060-210791374
   PubMed Web of Science ®Google Scholar
• Dokainish H. Combining tissue Doppler echocardiography and B-type natriuretic peptide in the evaluation of left ventricular filling pressures: review of the literature and clinical recommendations. Can J Cardiol. 2007;23(12):983–989. doi:10.1016/S0828-282X(07)70861-917932575
   PubMed Web of Science ®Google Scholar
• Zhang Z, Li R, Yang F, Xi L. Natriuretic peptide family as diagnostic/prognostic biomarker and treatment modality in management of adult and geriatric patients with heart failure: remaining issues and challenges. J Geriatric Cardiol. 2018;15(5):540–546.
   Google Scholar
• Chow SC, Liu JP. Classification of Clinical Trials, in Design and Analysis of Clinical Trials: Concepts and Methodologies. 2nd ed. Hoboken, NJ, USA: John Wiley & Sons, Inc 2004; doi:10.1002/0471473286.ch7
   Google Scholar
• Ho KL, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol. 1993;22(4):6A–13A. doi:10.1016/0735-1097(93)90455-A8509564
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. European Society of Cardiology guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail. 2016;18(8):891–975.27207191
   PubMed Web of Science ®Google Scholar
• Ajuluchukwu JN, Ekure EN, Mbakwem AC, Okoromah CN, Oladipo OO. Reliability and accuracy of point-of-care amino-terminal proBNP in congestive heart failure patients. Intern J Cardiol. 2010;9(1):1–15.
   Google Scholar
• Cockroft DW, Gault MH. Prediction of creatinine clearance from creatinine. Nephron. 1976;16(1):31–41. doi:10.1159/0001805801244564
   PubMed Web of Science ®Google Scholar
• WHO.WHO STEP wise Approach to surveillance (STEPS). Waist Circumference and Waist-Hip Ratio: Report of a WHO Expert Consultation. Geneva: World Health Organization (WHO), Geneva; 2008.
   Google Scholar
• Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendation for the evaluation of left ventricular diastolic dysfunction by echocardiography: an update of the ASE & European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29(4):277–314. doi:10.1016/j.echo.2016.01.01127037982
   PubMed Web of Science ®Google Scholar
• Lang RM, Badano LP, Mor-Avi V, et al. Recommendation for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1–39. doi:10.1016/j.echo.2014.10.00325559473
   PubMed Web of Science ®Google Scholar
• Nagueh SF, Smiseth OA, Appleton CP, et al. Diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J-Cardiovasc Imag. 2016;17(12):1321–1360. doi:10.1093/ehjci/jew082
   PubMed Web of Science ®Google Scholar
• Murdoch DR, McDonagh TA, Byrne J. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am Heart J. 1999;138(6):1126–1132. doi:10.1016/S0002-8703(99)70079-710577444
   PubMed Web of Science ®Google Scholar
• Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a Phase 2 double blind randomised controlled trial. The prospective comparison of ARNI with ARB in the management of heart failure with preserved ejection fraction. The Lancet. 2012;380(9851):1387–1395.
   PubMed Web of Science ®Google Scholar
• Hussain S, Kayani AM, Munir R. Effect of a regimen of optimal medical therapy on brain natriuretic peptide (BNP) levels in heart failure in the Pakistani population. Pak Heart J. 2012;45(1):17–21.
   Google Scholar
• Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P; For the Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347(3):161–167. doi:10.1056/NEJMoa02023312124404
   PubMed Web of Science ®Google Scholar
• SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293–302.2057034
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ; For the Randomized Aldactone Evaluation Study Investigators, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341(10):709–717. doi:10.1056/NEJM19990902341100110471456
   PubMed Web of Science ®Google Scholar
• CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomised trial. Lancet. 1999;353(9146):9–13.10023943
   PubMed Web of Science ®Google Scholar
• MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet. 1999;353(9169):2001–2007. doi:10.1016/S0140-6736(99)04440-210376614
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004. doi:10.1056/NEJMoa140907725176015
   PubMed Web of Science ®Google Scholar
• Heinrich K, Prendergast HM, Erickson T. Chronic digoxin toxicity and significantly elevated BNP levels in the presence of mild heart failure. Am J Emerg Med. 2005;23(4):561–562. doi:10.1016/j.ajem.2004.10.00916032632
   PubMed Web of Science ®Google Scholar
• Mark D, Mark R, Nicholls MG, et al. Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild stable heart failure. Circulation. 2006;113(7):977–985. doi:10.1161/CIRCULATIONAHA.105.56772716476851
   PubMed Web of Science ®Google Scholar
• Lancellotti P, Galderisi M, Edvardsen T, et al. Echo-Doppler estimation of left ventricular filling pressure: results of the multicentre EACVI Euro-filling study. Eur Heart J Cardiovasc Imaging. 2017;18(9):961–968. doi:10.1093/ehjci/jex06728444160
   PubMed Web of Science ®Google Scholar
• Andersen OS, Smiseth OA, Dokainish H, et al. Estimating left ventricular filling pressure by echocardiography. J Am Coll Cardiol. 2017;69(15):1937–1948. doi:10.1016/j.jacc.2017.01.05828408024
   PubMed Web of Science ®Google Scholar
• Balaney B, Medvedofsky D, Mediratta A, et al. Invasive validation of the echocardiographic assessment of left ventricular filling pressures using the 2016 diastolic guidelines: head-to-head comparison with the 2009 guidelines. J Am Soc Echocardiogr. 2018;31(1):79–88. doi:10.1016/j.echo.2017.09.00229111121
   PubMed Web of Science ®Google Scholar
• Sato K, Grant AD, Negishi K, et al. Reliability of updated left ventricular diastolic function recommendations in predicting elevated left ventricular filling pressure and prognosis. Am Heart J. 2017;189:28–39. doi:10.1016/j.ahj.2017.03.02228625379
   PubMed Web of Science ®Google Scholar
• Mak GS, DeMaria A, Clopton P, Maisel AS. Utility of b-type natriuretic peptide in the evaluation of left ventricular diastolic dysfunction: comparison with tissue Doppler imaging recordings. Am Heart J. 2004;148(5):895–902. doi:10.1016/j.ahj.2004.02.01615523324
   PubMed Web of Science ®Google Scholar
• Ojji DB, Opie LH, Lecour S, et al. The proposed role of plasma NT pro-brain natriuretic peptide in assessing cardiac remodelling in hypertensive African subjects. Cardiovasc J Afr. 2014;25(5):233–238. doi:10.5830/CVJA-2014-05025629540
   PubMed Web of Science ®Google Scholar
• Redfield MM, Rodcheffer RJ, Jacobsen SJ, et al. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol. 2002;40(5):976–982. doi:10.1016/S0735-1097(02)02059-412225726
   PubMed Web of Science ®Google Scholar
• Madamanchi C, Alhosaini H, Sumida A, Runge MS. Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure. Int J Cardiol. 2014;176(3):611–617. doi:10.1016/j.ijcard.2014.08.00725156856
   PubMed Web of Science ®Google Scholar
• Yandle TG, Richards AM. B-type natriuretic peptide circulating forms: analytical and bioactivity issues. Clin Chem Acta. 2015;448(6):195–205. doi:10.1016/j.cca.2015.07.004
   PubMedGoogle Scholar
• Martinez RA, Richards AM, Burnett JC, Januzzi JL Jr. Biology of the natriuretic peptides. Am J Cardiol. 2008;101(3A):3–8. doi:10.1016/j.amjcard.2007.11.01218243856
   PubMed Web of Science ®Google Scholar